By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Branch from The Black Box Warning

In Monday’s Black Box Warning, we met Ivy and Cherry the Picker, and their blank-label vial. Here's what happens when you actually run their claim through the Skeptic’s Toolkit.

Peptides like BPC-157 are pitched as a safe, natural alternative to the medicine you're scared of.

Peptides sound complicated, but the idea is simple. Your cells build proteins by reading instructions stored in DNA and copied into a working version, RNA. A peptide is what you get when that same process makes a short chain of amino acids, essentially a small fragment of a protein. Your body already runs on peptides. Insulin is one. Oxytocin is one. A newer wave of approved medicines, including semaglutide, the active ingredient in Ozempic and Wegovy, are peptides too, built the long way, through trials. BPC-157 is also a peptide. What's different isn't the molecule type. It's that BPC-157 has never gone through that same human testing and approval process.

Get the deck of questions: A Skeptic’s Toolkit — 10 Questions for Any Claim

1.      Who funded this, and do they have a stake in the answer? The influencer promoting it, whose income depends on you buying it.

2.        Am I applying the same standards to all claims? You read the drug's whole warning label and refuse it, then inject a vial with no label at all.

3.        How many people were studied, and has this been replicated? For BPC-157 in humans, almost none. The evidence is animal data and stories.

4.        Does the evidence match the use? The one review that just happened was scored for ulcerative colitis, using an enema. Nobody has tested the injectable form most people are actually using, for any indication.

Rooty's shorthand for all four of those questions: does it have a receipt? There's a two-minute game by that name that walks you through spotting the difference between a claim and a proof: openlabelmedia.com/does-it-have-a-receipt-2.

BPC-157 isn't approved, and it isn't banned either. The FDA pulled it out of one restricted list this April, then on July 23 its own advisory committee voted 8 to 6 to recommend it for the compounding list, over the objections of members who worried the vote would make it look more tested than it actually is. The FDA's own staff told the committee the safety and effectiveness data is thin. Nobody decided this is fine. A committee is split, and the agency still has to decide.

One more detail most coverage skipped: the committee's review was scored against ulcerative colitis, a specific gut condition, using an enema. The joint and muscle recovery use most people are actually buying it for, in the injectable form most people are actually using, was never the question in that room. And the one human trial in that file didn't even reach a statistically real effect. "Wolverine compound" is a marketing name. The file underneath it is a single unpublished abstract.

BPC-157 isn't the only peptide riding this same gray zone. Retatrutide, an Eli Lilly weight-loss drug still in clinical trials, has picked up the nickname “GLP-3” online. It works like the GLP-1 drugs you already know, Ozempic and Wegovy, except it also mimics a third hormone, glucagon, which is part of why some users report faster results.

It also isn't approved yet. That gap between “still being tested” and “already for sale” gets filled by overseas sellers who label the vials “not for human consumption, research use only,” then ship them anyway. Search “research peptides” online and you'll find dozens of storefronts doing exactly this, some selling dosing calculators and starter kits alongside a legal disclaimer that nobody buying seems to read. One retatrutide user described people who “just get these things and shoot them” as “out of their minds,” while defending his own supplier as trustworthy. A University of Michigan GLP-1 researcher was blunter: the unknowns “scare the crap out of” him. Buying that way skips a clinician checking your dose, a lab confirming what's actually in the vial, and anyone watching for side effects, the same gap Ivy and Cherry the Picker are selling you on with BPC-157, one indication over.

The move to keep: a long warning label means somebody did the work to find the risks. A blank label doesn't mean there are none. It means nobody looked. Think of it like two people arguing about a pressure washer. One says, “I saw it cut clean through a cake, it's incredible.” The other says, “okay, but does it actually clean my car?” Both things can be true. The pressure washer might genuinely be powerful. But cutting through a cake and cleaning a car are two different questions, and answering one doesn't answer the other.

That's roughly the shape of what happened here. The one human data point on record tested a narrow, specific question, given rectally, for ulcerative colitis, and it didn't reach statistical significance. It didn't test what most people buying BPC-157 today are actually asking, which is whether an injected dose helps a joint or a tendon heal faster. Powerful in one test doesn't mean proven for the other job.

The Wall of Sam’s

Add a comment and tell me: what's the "natural" claim you've been most tempted to trust without checking the label?

You just got the dinner-table version. Forward this to the person who needs it, and you are on your way to a Series 1 card.

Want Thursday and Friday too?

The Informed (Thursday) and The Verdict (Friday) do not come automatically. You have to turn them on yourself. It takes ten seconds and it is the only way the full week lands in your inbox. Opt-in Instructions

Try it yourself: see if you’d have caught this week's Black Box Warning costume on your own.

1)       The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type.

2)       Got Skepticism? runs any claim through the same one-question move Sam just used.

3)     Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.

The quiz and both games play in your browser at openlabelmedia.com, and I would love to see your results on social media!

[1] Literature and patent review of BPC-157 preclinical evidence (Pharmaceuticals, 2025).
[2] FDA Pharmacy Compounding Advisory Committee, BPC-157 vote, July 23, 2026 (fda.gov); reported same day by ABC News.
[3] FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (fda.gov/media/193343/download).
[4] Sharon Adarlo, “People Jabbing Themselves With Black Market ‘GLP-3’ Drugs,” Yahoo News, reporting on The Atlantic, Dec 29, 2025.

For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.

Instagram: instagram.com/roottorx  |  Facebook Lab: facebook.com/groups/theroottorxlab  |  TikTok: tiktok.com/@root.to.rx  |  YouTube: youtube.com/@roottorx  |  Threads: threads.com/@roottorx  |  Subscribe: RootToRx.com

You are receiving this because you subscribed at roottorx.com.

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States